Substance / Medication

Pamidronic acid

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

8 trials linked to this intervention

8
Total Trials
1
Recruiting
3
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Atrial fibrillation in patients treated with intravenous zoledronic or pamidronic acid: a pharmacoepidemiological study.
Pijnenburg Luc, Salem Joe-Elie, Lebrun-Vignes Bénédicte et al. · Eur J Endocrinol · 2021
PMID: 33449911Meta-Analysis
A Review Into the Effects of Pamidronic Acid and Zoledronic Acid on the Oral Mucosa in Medication-Related Osteonecrosis of the Jaw.
Bullock George, Miller Cheryl A, McKechnie Alasdair et al. · Front Oral Health · 2021
PMID: 35224540ReviewFull text (PMC)
Preparation, Optimisation, and In Vitro Evaluation of [F]AlF-NOTA-Pamidronic Acid for Bone Imaging PET.
Hassan Hishar, Othman Muhamad Faiz, Abdul Razak Hairil Rashmizal et al. · Molecules · 2022
PMID: 36432069OtherFull text (PMC)
Pamidronic acid-grafted nHA/PLGA hybrid nanofiber scaffolds suppress osteoclastic cell viability and enhance osteoblastic cell activity.
Haider Adnan, Versace Davy-Louis, Gupta Kailash Chandra et al. · J Mater Chem B · 2016
PMID: 32263816Other
Immobilization of pamidronic acids on the nanotube surface of titanium discs and their interaction with bone cells.
Koo Tae-Hyung, Borah Jyoti S, Xing Zhi-Cai et al. · Nanoscale Res Lett · 2013
PMID: 23497321OtherFull text (PMC)
Preparation, Characterization, and Radiolabeling of [Ga]Ga-NODAGA-Pamidronic Acid: A Potential PET Bone Imaging Agent.
Ashhar Zarif, Yusof Nor Azah, Ahmad Saad Fathinul Fikri et al. · Molecules · 2020
PMID: 32526838PreclinicalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Pamidronic acid (substance)
SNOMED CT
420442001
UMLS CUI
C3714572

Clinical Data

This intervention maps to 4 entities in the Ltrl knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
8
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.